Skip to content

Cardio-Oncology Rehabilitation Exercise

A Single Arm Intervention Study to Assess the Role of Structured Cardio-Oncology Rehabilitation Exercise to Improve Cardiovascular Health in Early Stage Breast Cancer Survivors (CORE Study)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05522959
Acronym
CORE
Enrollment
100
Registered
2022-08-31
Start date
2022-03-14
Completion date
2026-12-31
Last updated
2025-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Cardiac Rehabilitation, Cardio-oncology, Cardiometabolic Health, Cardiovascular Disease Risk

Brief summary

Women with breast cancer who are referred to the cardiac rehabilitation program at the Toronto Rehabilitation Institute will be invited to enrol in this observational study. Participants will take part in an established 16-week multimodal cardiac rehabilitation program (HEALTh program) at Toronto Rehabilitation Institute and outcome measures will be assessed before and after program participation to determine the effectiveness of the program in improving cardio metabolic health. Change in VO₂peak will be assessed using Cardiopulmonary Exercise Test (CPET). Traditional cardiac risk factors, lifestyle behaviours, exercise adherence, health-related quality of life, and fatigue will also be assessed.

Interventions

None listed

Sponsors

Toronto Rehabilitation Institute
CollaboratorOTHER
University of Toronto
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* History of early-stage breast cancer (I-III) * Currently receiving or have completed adjuvant therapy (i.e. chemotherapy, surgery, radiation, targeted therapies) * Able to communicate in English

Exclusion criteria

* Pregnancy * Metastatic disease (Stage IV) * Unable or unwilling to complete cardiopulmonary exercise test

Design outcomes

Primary

MeasureTime frameDescription
Cardiopulmonary Fitnesspost-intervention (16 weeks)VO2peak assessed using cardiopulmonary exercise test

Secondary

MeasureTime frameDescription
Native myocardial T1 timepost-intervention (16 weeks)Measured only in a subset (n=30) of participants via 1.5T MRI.
lipid profilepost-intervention (16 weeks)Assessed via fasting blood draw
Fasting glucosepost-intervention (16 weeks)Assessed via fasting blood draw
hemoglobin A1cpost-intervention (16 weeks)Assessed via fasting blood draw
Cancer-specific, health-related quality of lifepost-intervention (16 weeks)Functional Assessment of Cancer Therapy (FACT) questionnaire. Minimum score = 0, maximum score = 108, with higher score representing better quality of life.
Depressive symptomspost-intervention (16 weeks)Patient Health Questionnaire 9 scale. Minimum value = 0, maximum value = 27, where higher score represents more depressive symptoms.
Psychosocial Stresspost-intervention (16 weeks)Perceived Stress Scale (PSS). Minimum value = 0, maximum value = 56, where higher score represents more perceived stress.
Cancer-related fatiguepost-intervention (16 weeks)Fatigue sub-scale of the Functional Assessment of Cancer Therapy (FACT) questionnaire. Minimum score = 0, maximum score = 52, with higher score representing less fatigue.
Visceral adipose tissuepost-intervention (16 weeks)Measured only in a subset (n=30) of participants via 1.5T MRI.
Left ventricular ejection fractionpost-intervention (16 weeks)Measured only in a subset (n=30) of participants via 1.5T MRI.
Left ventricular masspost-intervention (16 weeks)Measured only in a subset (n=30) of participants via 1.5T MRI.

Other

MeasureTime frameDescription
Vigorous-intensity Physical Activityaveraged over 7 days post-interventionPiezoRx® will be worn by participants for 7 days with data used to assess vigorous activity time (\>120 steps per minute)
Physical Activity Bouts per Dayaveraged over 7 days post-interventionPiezoRx® will be worn by participants for 7 days with data used to assess bouts of physical activity per day (greater than 10 minutes of moderate/vigorous activity)
Total daily stepsaveraged over 7 days post-interventionPiezoRx® will be worn by participants for 7 days with data used to assess total daily steps
Self-Reported Physical Activitypost-intervention (16 weeks)Godin Leisure Time Physical Activity Questionnaire
Diet qualitypost-intervention (16 weeks)Rapid Eating and Activity Assessment for Participants (REAP) questionnaire. Minimum score = 13, maximum score = 39, with a higher score indicating a higher diet quality.
Smoking Statuspost-intervention (16 weeks)Smoking assessment history questionnaire
Moderate-Intensity Physical Activity Timeaveraged over 7 days post-interventionPiezoRx® will be worn by participants for 7 days with data used to assess moderate activity time (\>100 steps per minute)

Countries

Canada

Contacts

Primary ContactAmy A Kirkham, PhD
amy.kirkham@utoronto.ca(416) 946-4069‬‬

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026